Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registration-enabled study of TAVO™ (tavokinogene telseplasmid) in combination with KEYTRUDA in women with recurrent/persistent cervical cancer

Next Previous
X
Search
Trial Profile

Registration-enabled study of TAVO™ (tavokinogene telseplasmid) in combination with KEYTRUDA in women with recurrent/persistent cervical cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary)
  • Indications Cervical cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors OncoSec Medical

    • Most Recent Events

    • 01 Feb 2019 According to an OncoSec Medical media release, company expect to dose first patient in 1H 2019.
    • 01 Feb 2019 According to an OncoSec Medical media release, regulatory filling in U.S. is anticipated in 2021.
    • 01 Feb 2019 According to an OncoSec Medical media release, study preparations are underway with first site initiation and patient enrollment expected to begin in the U.S. in the first half of 2019, with potential expansion into other countries

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top